A system includes a chip-receiving component, a first fluid processing assembly, a second fluid processing assembly, and a fluid communication pathway. The chip-receiving component is to receive a process chip having microfluidic passageways. The first fluid processing assembly is to communicate fluids to microfluidic passageways of a process chip received by the chip-receiving component. The second fluid processing assembly includes a sample support feature to support sample containers. The second fluid processing assembly also includes a plurality of sampling heads to selectively communicate fluids from sample containers supported by the sample support feature. The fluid communication pathway includes a plurality of conduits to provide fluid communication between the first fluid processing assembly and the plurality of sampling heads. The first fluid processing assembly is to further communicate fluids from the fluid communication pathway to microfluidic passageways of a process chip received by the chip-receiving component.
Disclosed are methods and systems for the purification of mRNA, for example therapeutic mRNAs, which yields one or more benefits such as increased purification yields, reduced double -stranded RNA following purification. The methods may be used in conjunction with a biochip and/or automated methods.
Microfluidic apparatuses (e.g., systems, devices, etc.) and methods for microfluidic provide detection of polynucleotide concentration. These apparatuses may include removable, single-use or reusable microfluidic members that may include one or more channels, chambers and/or substrates for performing microfluidic maneuvers and are adapted for detection of polynucleotide concentration. For example, the microfluidic member may be a microfluidic cartridge that may be inserted, held and/or seated in a microfluidic driver apparatus that may oversee and control operations within one or more cartridges based in part on the detected concentration of polynucleotide.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
An apparatus includes a process chip and a dynamic light scattering assembly. The process chip includes a fluid chamber including and an optically transmissive material adjacent to the fluid chamber. The process chip is to be removably positioned in relation to the dynamic light scattering assembly. The dynamic light scattering assembly is to direct the light through the optically transmissive material and into the fluid chamber. The dynamic light scattering assembly is further to receive light scattered by particles in fluid in the fluid chamber in response to the first optical fiber emitting light into the fluid chamber and thereby capture light scattering data. A processor determines viscosity of fluid in the fluid chamber based on the captured light scattering data. The processor also determines one or both of size or size distribution of particles in the fluid based the captured light scattering data.
A fluidic apparatus includes a first layer defining a first chamber portion configured to receive pressurized gas. The apparatus also includes a second layer defining a second chamber portion positioned under the first chamber portion and configured to receive a liquid and a plurality of particles, a fluid outlet channel in fluid communication with the second chamber portion, and a filter interposed between the second chamber portion and the fluid outlet channel. The filter is formed in a surface of the second layer. The apparatus further includes an elastic layer disposed between the first layer and the second layer, the elastic layer being deformable into the second chamber portion to thereby drive the liquid out of the second chamber portion through the filter and into the fluid outlet channel. The filter is configured to permit the liquid to flow therethrough, and to prevent the particles from flowing therethrough.
The present disclosure provides novel methods for assessing product related impurities, such as protein aggregation, in a biological sample comprising a size exclusion chromatography (SEC) and an automated capillary electrophoresis (CE) western. Specifically, the present disclosure provides method for assessing protein aggregation in an unpurified biological sample comprising an in vivo or in vitro produced protein and/or aggregates thereof.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
B01D 15/34 - Size-selective separation, e.g. size-exclusion chromatographyGel filtrationPermeation
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
C07K 1/16 - ExtractionSeparationPurification by chromatography
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
Provided herein are compounds that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped miRNA molecules, wherein the 5′ end of the RNA molecule comprises a cap analog disclosed herein, drug products comprising the capped RNA molecules, methods for making capped polynucleotides disclosed herein, and kits for making the capped polynucleotides.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
The present disclosure provides delivery vehicle compositions comprising degradable peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
9.
MULTIPLE SPECIFIC ANTIBODIES TARGETING CD19, CD20, AND/OR CD47
The disclosure relates generally to multi-specific antibodies that specifically bind to two or more different antigens and comprising a signal -regulatory protein alpha protein, nucleic acids encoding the multi-specific antibodies, and compositions comprising the multi-specific antibodies or nucleic acids. The disclosure also relates to in vivo methods of making these multi-specific antibodies.
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
10.
MULTIVALENT ANTIBODY CONSTRUCTS FOR TARGETING PROSTATE CANCER CELLS
Disclosed are multispecific antibody constructs, and polynucleotides encoding for same, the proteins and antibody constructs being useful for the treatment of prostate cancer. The disclosed proteins and antibody constructs comprise at least one antigen binding domain that specifically binds to at least one prostate cancer cell specific antigen. The disclosed proteins and antibody constructs may further comprise at least one binding domain that specifically binds to a T-cell specific antigen, which may be used to form a multispecific T-cell engager molecule useful for the treatment of prostate cancer. Further disclosed are methods of making and using the disclosed compositions.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A fluidic apparatus includes a first layer defining first and second chamber portions, which are configured to receive pressurized gas. A second layer defines third and fourth chamber portions, which each have a respective sidewall defining a recess and a fluid receiving volume adjacent to the recess. The third chamber portion is positioned under the first chamber portion. The fourth chamber portion is positioned under the second chamber portion. A fluid path extends from the recess in the sidewall of the third chamber portion to the recess in the sidewall of the fourth chamber portion, providing a path for communication of fluid from the third chamber to the fourth chamber portion. An elastic layer disposed between the first layer and the second layer is deformable into the fluid receiving volume of the third chamber portion to thereby drive fluid into the fluid receiving volume of the fourth chamber portion.
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
09 - Scientific and electric apparatus and instruments
Goods & Services
Microfluid instrumentation for controlling bioprocesses
(term considered too vague by the International Bureau
pursuant to Rule 13 (2) (b) of the Regulations).
Provided herein are compounds that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped mRNA molecules, wherein the 5′ end of the RNA molecule comprises a cap analog disclosed herein, drug products comprising the capped RNA molecules, methods for making capped polynucleotides disclosed herein, and kits for making the capped polynucleotides.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Provided herein are compounds that are cap analogs for polynucleotides that bear a N-ethylguanosine moiety, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped mRNA molecules, wherein the 5' end of the RNA molecule comprises a cap analog disclosed herein, drug products comprising the capped RNA molecules, methods for making capped polynucleotides disclosed herein, and kits for making the capped polynucleotides. (I)
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
09 - Scientific and electric apparatus and instruments
Goods & Services
Scientific apparatus and instruments for the manufacture of therapeutic products, namely, a microfluidics biochip-based manufacturing platform for the production of RNA therapeutics; Scientific apparatus and instruments for manufacturing therapeutics, namely, a microfluidics biochip-based manufacturing platform for the production of RNA therapeutics
19.
MIXING AND MICROFLUIDIC APPARATUSES RELATED THERETO
The application relates to microfluidic apparatus and methods of use thereof. Provided in one example is a microfluidic device comprising: a first fluidic input and a second fluidic input; and a fluidic intersection channel to receive fluid from the first fluidic input and the second fluidic input, wherein the fluidic intersection channel opens into a first mixing chamber on an upper region of a first side of the first mixing chamber, wherein the first mixing chamber has a length, a width, and a depth, wherein the depth is greater than about 1.5 times a depth of the fluidic intersection channel; an outlet channel on an upper region of a second side of the first mixing chamber, wherein the outlet channel has a depth that is less than the depth of the first mixing chamber, and wherein an opening of the outlet channel is offset along a width of the second side of the first mixing chamber relative to the fluidic intersection.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
B01F 23/40 - Mixing liquids with liquidsEmulsifying
B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
A customized codon sequence may be generated using a method which comprises receiving a target amino acid sequence, generating a plurality of candidate codon sequences, and selecting, from a set of final codon sequences which comprises candidate codon sequences, a customized codon sequence. In such a method, each of the candidate codon sequences may be a codon sequence which codes for the target amino acid sequence, and the final codon sequences may be generated based on a set of initial codon sequences. Additionally, the final codon sequences may be organized into sets of final codon sequences, each of which sets corresponds to a vector from a set of vectors and may comprise codon sequences which are farther from an origin than typical codon sequence from a set of initial codon sequences. Corresponding systems and computer readable mediums for generating customized codon sequences may also be implemented.
Disclosed herein are methods for analyzing a nucleic acid encapsulated in a lipid nanoparticle (LNP). In one aspect, the methods may comprise solubilizing an LNP with a nonionic surfactant to form an analyte sample, introducing the analyte sample into a capillary, and detecting the nucleic acid via capillary electrophoresis (CE). In certain aspects, the nonionic surfactant may comprise from about 1% to about 10% v/v of the analyte sample.
An example system includes a plurality of scriptable devices, each of which exposes an interface. The system may also comprise a medium storing data indicating, for each of a mapped plurality of device operations, one or more inputs to provide to a corresponding device from the plurality of scriptable devices and a conversion between that device operation and a corresponding application command. In such a system, the medium may also store a plurality of scripts, each of which may have a corresponding scriptable device from the plurality of scriptable devices and may comprise a set of device operations. The system may also comprise a computer to repeatedly preform an operation cycle comprising determining whether an application command should be executed and, when it should, generating a globally unique identifier corresponding to that command and adding that globally unique identifier and a device operation corresponding to that command to a log.
An apparatus includes a process chip (800) and a dynamic light scattering assembly. The process chip (800) may be removably positioned in relation to the dynamic light scattering assembly. The process chip (800) includes a fluid chamber (802). The dynamic light scattering assembly includes a body (900), a first optical fiber (1010), and a second optical fiber (1020). The body (900) may be positioned proximate to an exterior surface of the process chip (800). A first port of the body is to direct light emitted by the first optical fiber (1010) through optically transmissive material of the process chip (800) and into the fluid chamber (802). The second optical fiber (1020) is oriented obliquely relative to the first optical fiber (1010). The second optical fiber (1020) is to receive light scattered by particles in fluid in the fluid chamber (802) in response to the first optical fiber (1010) emitting light into the fluid chamber (802).
G01N 15/0205 - Investigating particle size or size distribution by optical means
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 1/38 - Diluting, dispersing or mixing samples
G01N 11/00 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
25.
SYSTEMS AND METHODS FOR GENERATING NUCLEOTIDE SEQUENCE SYNTHESIS RELATED METRICS
Provided in one example is a system that includes one or more processors to receive a sequence data structure; apply at least one first metric of a plurality of metrics to the sequence data structure to generate at least one first metric score; determine that the at least one first metric score satisfies a first condition; apply, responsive to the at least one first metric score satisfying the first condition, at least one second metric of the plurality of metrics to the sequence data structure to generate at least one second metric score; and output an indication of the at least one first metric score and the at least one second metric score.
Provided herein are compounds according to formula (I), wherein each of R7 and R8 is H or C1-C6-alkyl and at least one of R7 and R8 is C1-C6-alkyl, that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped mRNA molecules, wherein the 5' end of the RNA molecule comprises a cap analog disclosed herein, drug products comprising the capped RNA molecules, methods for making capped polynucleotides disclosed herein, and kits for making the capped polynucleotides.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/67 - General methods for enhancing the expression
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.
A microfluidic apparatus includes a first plate, a second plate, and a microfluidic path defined between the first plate and the second plate. The microfluidic path includes at least one chamber. The microfluidic apparatus also includes an elastic layer disposed between the first plate and the second plate. The elastic layer includes a first membrane extending across the at least one chamber. The first membrane is configured to deflect to drive a fluid through the at least one chamber. The elastic layer also includes a second membrane having at least one aperture. The at least one aperture is aligned with the at least one chamber.
The present disclosure provides delivery vehicle compositions comprising hydroxyethyl-capped tertiary amino lipidated cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
Microfluidic apparatuses including concentrators and buffer exchange regions that concentrate and exchange buffer. Also described are methods of passing a solution through a feed channel, filtering small molecules out of the feed channel by tangential flow filtration into a permeate channel adjacent to the first feed channel while maintaining a constant sheer rate relative to the membrane separating the feed channel from the permeate channel and exchanging buffer into the solution and concentrating the solution in a second region of the apparatus.
The presently described and disclosed technology includes, in one example, a method, comprising: extracting a sequence of a spike protein of a first virus from a first non-human mammal that is previously exposed to an infection by the first virus; identifying a target antigen specific to the spike protein; and injecting an mRNA therapeutic comprising an mRNA encoding the target antigen into a human patient that has antibodies to a second virus.
A system includes an optical sensor and a processor. The optical sensor has a field of view positioned to include a first fluid channel defined by a body. The processor receives a first image including a region of interest of the first fluid channel. The processor further receives a second image including the region of interest of the first fluid channel. The second image is captured after the first image. The processor further generates a comparison of the second image to the first image, generates a binary image using the comparison, and uses the binary image to determine whether a fluid is present in the region of interest of the first fluid channel. If the processor determines that the fluid is present in the region of interest of the first fluid channel, the processor ceases communication of the fluid through the first fluid channel.
Apparatuses and methods are described herein for processing polynucleotides in a sealed path environment. The apparatuses include optical sensors to monitor operations and to track material usage for good manufacturing practice.
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
09 - Scientific and electric apparatus and instruments
Goods & Services
(1) Microfluid instrumentation for controlling bioprocesses (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations).
A system includes a chip-receiving component, a first fluid processing assembly, a second fluid processing assembly, and a fluid communication pathway. The chip-receiving component is to receive a process chip having microfluidic passageways. The first fluid processing assembly is to communicate fluids to microfluidic passageways of a process chip received by the chip-receiving component. The second fluid processing assembly includes a sample support feature to support sample containers. The second fluid processing assembly also includes a plurality of sampling heads to selectively communicate fluids from sample containers supported by the sample support feature. The fluid communication pathway includes a plurality of conduits to provide fluid communication between the first fluid processing assembly and the plurality of sampling heads. The first fluid processing assembly is to further communicate fluids from the fluid communication pathway to microfluidic passageways of a process chip received by the chip-receiving component.
A method includes incubation of an amplification mixture containing uracil-DNA glycosy lase enzyme (UNG enzyme), a deoxyribonucleotide triphosphate (dNTP) mixture, a DNA polymerase, a template including a sequence of interest, and at least one primer pair, inactivation of UNG enzyme in the amplification mixture, and amplification of a sequence of interest to form an in vitro transcription template. The in vitro transcription template may be used to produce a therapeutic polynucleotide.
A system includes a chip-receiving component, a first fluid processing assembly, a second fluid processing assembly, and a fluid communication pathway. The chip-receiving component is to receive a process chip having microfluidic passageways. The first fluid processing assembly is to communicate fluids to microfluidic passageways of a process chip received by the chip-receiving component. The second fluid processing assembly includes a sample support feature to support sample containers. The second fluid processing assembly also includes a plurality of sampling heads to selectively communicate fluids from sample containers supported by the sample support feature. The fluid communication pathway includes a plurality of conduits to provide fluid communication between the first fluid processing assembly and the plurality of sampling heads. The first fluid processing assembly is to further communicate fluids from the fluid communication pathway to microfluidic passageways of a process chip received by the chip-receiving component.
The disclosure provides materials in the form of nanoparticles containing in vitro-transcribed mRNAs encoding antigenic peptides and personalized medicine methods for treating or preventing diseases such as cancer, an autoimmune disease, an infectious disease, or inflammation, wherein cells of a subject receiving prophylactic or therapeutic treatment are brought into contact with the nanoparticles ex vivo, and the subject's cells process the mRNA. expressing and presenting the encoded product to activate the subject's own T cells. thereby mounting an immune response to the diseased cells. such as cancer cells.
Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
An apparatus includes a sensing region. A flexible membrane positioned in the sensing region defines a plane, a radial center, and a central axis extending perpendicularly relative to the plane at the radial center. The membrane deforms along the central axis and along a lateral dimension using at least a property of fluid (e.g., pressure or density) in the sensing region. The lateral dimension is transverse to the central axis. An optical feature changes a visual state in response to deformation of the membrane along the lateral dimension. A camera is positioned to view the optical feature and capture images of the optical feature.
G01F 1/38 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects by measuring pressure or differential pressure the pressure or differential pressure being created by the use of flow constriction the pressure or differential pressure being measured by means of a movable element, e.g. diaphragm, piston, Bourdon tube or flexible capsule
G05D 7/06 - Control of flow characterised by the use of electric means
An apparatus includes a process chip and a dynamic Sight scattering assembly. The process chip includes a fluid chamber including and an optically transmissive material adjacent to the fluid chamber. The process chip is to be removably positioned m relation to the dynamic light scattering assembly. The dynamic light scattering assembly is to direct the light through the optically transmissive material and into the fluid chamber. The dynamic light scattering assembly is further to receive light scattered by particles in fluid in the fluid chamber in response to the first optical fiber emitting light into the fluid chamber and. thereby capture light scattering data, A processor determines viscosity of fluid in the fluid chamber based on the captured light scattering data. The processor also determines one or both of size or size distribution of particles in the fluid based the captured light scattering data.
The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
Provided herein is a method of making, comprising transporting reagents to a reactor in a microfluidic path device, wherein the reagents include a synthetic gene of interest, a polymerase, a buffer, a first primer having a first region specific to the synthetic gene of interest, and a second primer, wherein the second primer comprises a poly-T sequence of ≥150 base pairs (bp) or a poly-A sequence of ≥150 bp and a second region specific to the synthetic gene of interest; controlling a temperature of the first reactor to perform a polymerase chain reaction within the microfluidic path device to amplify the synthetic gene of interest using the first primer and the second primer to form a synthetic product including the poly-A sequence of ≥150 bp; and transporting the synthetic product out of the first reactor, wherein the synthetic product comprises a synthetic DNA template for in vitro transcription.
Filling systems and related container assemblies and methods are disclosed. In an implementation, a container assembly includes a container array, covers, a framework, and a fluidic network. The container array includes containers having distal ends and the covers are coupled to the respective distal ends of the containers. The framework is integral with: 1) the containers, 2) the covers and couples the containers together, or 3) both. The fluidic network includes fluidic channels that are defined by the framework and enable the containers to be filled in series or in parallel.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
B65B 55/02 - Sterilising, e.g. of complete packages
B65D 21/02 - Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together
48.
2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY
The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
Microfluidic apparatuses (e g., systems, devices, etc.) and methods for microfluidic provide detection of polynucleotide concentration. These apparatuses may include removable, single-use or reusable microfluidic members that may include one or more channels, chambers and/or substrates for performing microfluidic maneuvers and are adapted for detection of polynucleotide concentration. For example, the microfluidic member may be a microfluidic cartridge that may be inserted, held and/or seated in a microfluidic driver apparatus that may oversee and control operations within one or more cartridges based in part on the detected concentration of polynucleotide.
Human SIRPa fusion proteins having an enhanced affinity to CD47 via increased binding valency. The human SIRPa fusion proteins described herein may form tetramer, hexamer, octamers, etc. These fusion proteins may be configured to form heterodimers with other fusion proteins, including C-C chemokine receptor type 4 (CCR4) binding fusion proteins.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Apparatuses and methods are described herein for processing polynucleotides in a sealed path environment. The apparatuses include optical sensors to monitor operations and to track material usage for good manufacturing practice.
Apparatuses and methods are described herein for processing polynucleotides in a sealed path environment. The apparatuses include optical sensors to monitor operations and to track material usage for good manufacturing practice.
Provided herein are compounds that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped mRNA molecules, wherein the 5' end of the RNA molecule comprises a cap analog disclosed herein, drug products comprising the capped RNA molecules, methods for making capped polynucleotides disclosed herein, and kits for making the capped polynucleotides.
C07D 473/02 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
An example system includes a plurality of scriptable devices, each of which exposes an interface. The system may also comprise a medium storing data indicating, for each of a mapped plurality of device operations, one or more inputs to provide to a corresponding device from the plurality of scriptable devices and a conversion between that device operation and a corresponding application command. In such a system, the medium may also store a plurality of scripts, each of which may have a corresponding scriptable device from the plurality of scriptable devices and may comprise a set of device operations. The system may also comprise a computer to repeatedly preform an operation cycle comprising determining whether an application command should be executed and, when it should, generating a globally unique identifier corresponding to that command and adding that globally unique identifier and a device operation corresponding to that command to a log.
The application relates to microfluidic apparatus and methods of use thereof. Provided in one example is a microfluidic device comprising: a first fluidic input and a second fluidic input; and a fluidic intersection channel to receive fluid from the first fluidic input and the second fluidic input, wherein the fluidic intersection channel opens into a first mixing chamber on an upper region of a first side of the first mixing chamber, wherein the first mixing chamber has a length, a width, and a depth, wherein the depth is greater than about 1.5 times a depth of the fluidic intersection channel; an outlet channel on an upper region of a second side of the first mixing chamber, wherein the outlet channel has a depth that is less than the depth of the first mixing chamber, and wherein an opening of the outlet channel is offset along a width of the second side of the first mixing chamber relative to the fluidic intersection.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
B01F 23/40 - Mixing liquids with liquidsEmulsifying
B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
Polynucleotides, scaffolds, and cassettes are presently disclosed and described. In particular, these polynucleotides may have a formula comprising Signal/Leader-payload-PRM, wherein the Signal/Leader encodes a signal sequence, a leader sequence, or a sorting sequence, in frame with and upstream of a payload; the payload is an antigenic payload region, a detectable agent, and a therapeutic agent; and the PRM encodes all or a portion of at least one parental receptor molecule region from one or more isoforms or proteins selected from the group consisting of CD1d, CD1e, LDLR, LDLRP, and LRP1 proteins.
Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided in one example is a system that includes one or more processors to receive a sequence data structure; apply at least one first metric of a plurality of metrics to the sequence data structure to generate at least one first metric score; determine that the at least one first metric score satisfies a first condition; apply, responsive to the at least one first metric score satisfying the first condition, at least one second metric of the plurality of metrics to the sequence data structure to generate at least one second metric score; and output an indication of the at least one first metric score and the at least one second metric score.
An example system includes a plurality of scriptable devices, each of which exposes an interface. The system may also comprise a medium storing data indicating, for each of a mapped plurality of device operations, one or more inputs to provide to a corresponding device from the plurality of scriptable devices and a conversion between that device operation and a corresponding application command. In such a system, the medium may also store a plurality of scripts, each of which may have a corresponding scriptable device from the plurality of scriptable devices and may comprise a set of device operations. The system may also comprise a computer to repeatedly preform an operation cycle comprising determining whether an application command should be executed and, when it should, generating a globally unique identifier corresponding to that command and adding that globally unique identifier and a device operation corresponding to that command to a log.
An example system includes a plurality of scriptable devices, each of which exposes an interface. The system may also comprise a medium storing data indicating, for each of a mapped plurality of device operations, one or more inputs to provide to a corresponding device from the plurality of scriptable devices and a conversion between that device operation and a corresponding application command. In such a system, the medium may also store a plurality of scripts, each of which may have a corresponding scriptable device from the plurality of scriptable devices and may comprise a set of device operations. The system may also comprise a computer to repeatedly preform an operation cycle comprising determining whether an application command should be executed and, when it should, generating a globally unique identifier corresponding to that command and adding that globally unique identifier and a device operation corresponding to that command to a log.
The presently described and disclosed technology includes, in one example, a method, comprising: extracting a sequence of a spike protein of a first virus from a first non-human mammal that is previously exposed to an infection by the first virus; identifying a target antigen specific to the spike protein; and injecting an mRNA therapeutic comprising an mRNA encoding the target antigen into a human patient that has antibodies to a second virus.
The present disclosure provides delivery vehicle compositions comprising hydroxyethyl-capped tertiary amino lipidated cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
An apparatus includes a process chip and a dynamic light scattering assembly. The process chip includes a fluid chamber including and an optically transmissive material adjacent to the fluid chamber. The process chip is to be removably positioned in relation to the dynamic light scattering assembly. The dynamic light scattering assembly is to direct the light through the optically transmissive material and into the fluid chamber. The dynamic light scattering assembly is further to receive light scattered by particles in fluid in the fluid chamber in response to the first optical fiber emitting light into the fluid chamber and thereby capture light scattering data. A processor determines viscosity of fluid in the fluid chamber based on the captured light scattering data. The processor also determines one or both of size or size distribution of particles in the fluid based the captured light scattering data.
A system includes an optical sensor and a processor. The optical sensor has a field of view positioned to include a first fluid channel defined by a body. The processor receives a first image including a region of interest of the first fluid channel. The processor further receives a second image including the region of interest of the first fluid channel. The second image is captured after the first image. The processor further generates a comparison of the second image to the first image, generates a binary image using the comparison, and uses the binary image to determine whether a fluid is present in the region of interest of the first fluid channel. If the processor determines that the fluid is present in the region of interest of the first fluid channel, the processor ceases communication of the fluid through the first fluid channel.
A system includes a chip-receiving component, a first fluid processing assembly, a second fluid processing assembly, and a fluid communication pathway. The chip¬ receiving component is to receive a process chip having microfluidic passageways. The first fluid processing assembly is to communicate fluids to microfluidic passageways of a process chip received by the chip-receiving component. The second fluid processing assembly includes a sample support feature to support sample containers. The second fluid processing assembly also includes a plurality of sampling heads to selectively communicate fluids from sample containers supported by the sample support feature. The fluid communication pathway includes a plurality of conduits to provide fluid communication between the first fluid processing assembly and the plurality of sampling heads. The first fluid processing assembly is to further communicate fluids from the fluid communication pathway to microfluidic passageways of a process chip received by the chip-receiving component.
A method includes incubation of an amplification mixture containing uracil-DNA glycosylase enzyme (UNG enzyme), a deoxyribonucleotide triphosphate (dNTP) mixture, a DNA polymerase, a template including a sequence of interest, and at least one primer pair, inactivation of UNG enzyme in the amplification mixture, and amplification of a sequence of interest to form an in vitro transcription template. The in vitro transcription template may be used to produce a therapeutic polynucleotide.
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
An apparatus includes a process chip (800) and a dynamic light scattering assembly. The process chip (800) may be removably positioned in relation to the dynamic light scattering assembly. The process chip (800) includes a fluid chamber (802). The dynamic light scattering assembly includes a body (900), a first optical fiber (1010), and a second optical fiber (1020). The body (900) may be positioned proximate to an exterior surface of the process chip (800). A first port of the body is to direct light emitted by the first optical fiber (1010) through optically transmissive material of the process chip (800) and into the fluid chamber (802). The second optical fiber (1020) is oriented obliquely relative to the first optical fiber (1010). The second optical fiber (1020) is to receive light scattered by particles in fluid in the fluid chamber (802) in response to the first optical fiber (1010) emitting light into the fluid chamber (802).
The application relates to microfluidic apparatus and methods of use thereof. Provided in one example is a microfluidic device comprising: a first fluidic input and a second fluidic input; and a fluidic intersection channel to receive fluid from the first fluidic input and the second fluidic input, wherein the fluidic intersection channel opens into a first mixing chamber on an upper region of a first side of the first mixing chamber, wherein the first mixing chamber has a length, a width, and a depth, wherein the depth is greater than about 1.5 times a depth of the fluidic intersection channel; an outlet channel on an upper region of a second side of the first mixing chamber, wherein the outlet channel has a depth that is less than the depth of the first mixing chamber, and wherein an opening of the outlet channel is offset along a width of the second side of the first mixing chamber relative to the fluidic intersection.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
B01F 23/40 - Mixing liquids with liquidsEmulsifying
B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
70.
LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY
The present disclosure relates to complexes and compositions of cationic compounds combined with low mass percentages of PEGylated compounds, such as PEGylated lipids, for the delivery of nucleic acids and other polyanionic cargoes to cells, methods for preparing complexes and compositions comprising one or more cationic compounds and a low mass percentage of PEGylated compounds with polyanionic compounds, and methods for delivering the polyanionic compounds to cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
71.
MATERIALS AND METHODS FOR GENERATING ANTIGEN-SPECIFIC T CELLS AND TREATING DISEASES
The disclosure provides materials in the form of nanoparticles containing in vitro-transcribed mRNAs encoding antigenic peptides and personalized medicine methods for treating or preventing diseases such as cancer, an autoimmune disease, an infectious disease, or inflammation, wherein cells of a subject receiving prophylactic or therapeutic treatment are brought into contact with the nanoparticles ex vivo, and the subject's cells process the mRNA, expressing and presenting the encoded product to activate the subject's own T cells, thereby mounting an immune response to the diseased cells, such as cancer cells.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
72.
Microfluidic apparatuses and methods of use thereof in mixing
The application relates to microfluidic apparatus and methods of use thereof. Provided in one example is a microfluidic device comprising: a first fluidic input and a second fluidic input; and a fluidic intersection channel to receive fluid from the first fluidic input and the second fluidic input, wherein the fluidic intersection channel opens into a first mixing chamber on an upper region of a first side of the first mixing chamber, wherein the first mixing chamber has a length, a width, and a depth, wherein the depth is greater than about 1.5 times a depth of the fluidic intersection channel; an outlet channel on an upper region of a second side of the first mixing chamber, wherein the outlet channel has a depth that is less than the depth of the first mixing chamber, and wherein an opening of the outlet channel is offset along a width of the second side of the first mixing chamber relative to the fluidic intersection.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
B01F 23/40 - Mixing liquids with liquidsEmulsifying
B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
F04B 19/00 - Machines or pumps having pertinent characteristics not provided for in, or of interest apart from, groups
73.
APPARATUS WITH OPTICAL FEATURE CHANGING VISUAL STATE
An apparatus includes a sensing region. A flexible membrane positioned in the sensing region defines a plane, a radial center, and a central axis extending perpendicularly relative to the plane at the radial center. The membrane deforms along the central axis and along a lateral dimension using at least a property of fluid (e.g., pressure or density) in the sensing region. The lateral dimension is transverse to the central axis. An optical feature changes a visual state in response to deformation of the membrane along the lateral dimension. A camera is positioned to view the optical feature and capture images of the optical feature.
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
74.
MICROFLUIDIC CONCENTRATION AND BUFFER EXCHANGE APPARATUSES AND METHODS
Microfluidic apparatuses including concentrators and buffer exchange regions that concentrate and exchange buffer. Also described are methods of passing a solution through a feed channel, filtering small molecules out of the feed channel by tangential flow filtration into a permeate channel adjacent to the first feed channel while maintaining a constant sheer rate relative to the membrane separating the feed channel from the permeate channel and exchanging buffer into the solution and concentrating the solution in a second region of the apparatus.
Filling systems and related container assemblies and methods are disclosed. In an implementation, a container assembly includes a container array, covers, a framework, and a fluidic network. The container array includes containers having distal ends and the covers are coupled to the respective distal ends of the containers. The framework is integral with: 1) the containers, 2) the covers and couples the containers together, or 3) both. The fluidic network includes fluidic channels that are defined by the framework and enable the containers to be filled in series or in parallel.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65D 21/02 - Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Active chemical ingredients, including m-RNA, for use in the
manufacture of anti-cancer drugs; chemical solutions and
preparations consisting of pre-mixed reactants and reagents
for scientific and research use in connection with
transcription and translation of nucleic acid; chemical
solutions and preparations consisting of pre-mixed reactants
and reagents used to transfect nucleic acid into cells in
the field of scientific research; active chemical
ingredients for use in manufacture of anti-cancer drugs;
protein arrays and nucleotide arrays for scientific use;
nucleic acids, proteins and peptides for laboratory use;
diagnostic preparations for scientific or research use other
than for medical purposes. Protein arrays and nucleotide arrays for medical laboratory
use; diagnostic preparations for clinical or medical
laboratory use. Cartridges and DNA chips to receive and preserve biological
samples for use in RNA transcription; scientific apparatus
and instruments for manufacturing m-RNA and parts and
fittings therefore; laboratory apparatus and instruments for
transcription of RNA from DNA and translation to m-RNA;
scientific apparatus for receiving DNA samples, transcribing
RNA, and producing m-RNA molecules for use in identifying
and/or manufacturing therapeutic drugs to treat human
diseases. Compiling of data in computer databases for research
purposes in the field of medical science and medical
consultancy. Consulting services in the fields of biotechnology,
pharmaceutical research and development and genetic
sciences; dna analysis services for scientific research
purposes; medical and scientific research, in particular in
the fields of prevention and treatment cancer; providing
scientific research information, consultancy, and advisory
services, in particular in the fields of prevention and
treatment of cancer treatment; conducting early evaluations
in the field of new pharmaceuticals; consulting services in
the fields of biotechnology and pharmaceutical research;
pharmaceutical product development services; pharmaceutical
product evaluation services; pharmaceutical research and
development; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; research and development of pharmaceuticals for the
treatment of cancer; technical research in the field of
pharmaceutical studies; development of platform technology,
namely, cancer immunotherapy platforms for manufacturing
therapeutics; and consulting services for others in the
field of design, planning, and implementation of clinical
trials; design, engineering, research, development and
testing services in the field of nucleic acid sciences for
medical, scientific and technological applications;
scientific research; scientific research in the fields of
pharmaceuticals, medicine, biologics, biotherapeutics,
biosimilars and therapeutics.
78.
MULTICOMPONENT DELIVERY SYSTEMS FOR POLYANIONIC CARGO COMPOUND DELIVERY
The present disclosure relates to multicomponent delivery systems for delivering polyanionic cargo compounds, such as nucleic acids. The present disclosure also relates to methods of preparing and using the multicomponent delivery systems.
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
79.
Tertiary amino lipidated cationic peptides for nucleic acid delivery
The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present disclosure relates to lipid mixtures comprising lipidated cationic peptide compounds, such as tertiary amino lipidated and/or PEGylated cationic peptide compounds or lipitoids, for nucleic acid delivery. More specifically, the present disclosure relates to lipid nanoparticle formulations comprising lipidated cationic peptide compounds and other lipid components including structural lipid, phospholipid and shielding lipids. The present disclosure also relates to methods of preparing and using the lipid mixtures.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Polynucleotides, scaffolds, and cassettes are presently disclosed and described. In particular, these polynucleotides may have a formula comprising Signal/Leader-payload-PRM, wherein the Signal/Leader encodes a signal sequence, a leader sequence, or a sorting sequence, in frame with and upstream of a payload; the payload is an antigenic payload region, a detectable agent, and a therapeutic agent; and the PRM encodes all or a portion of at least one parental receptor molecule region from one or more isoforms or proteins selected from the group consisting of CD1d, CD1e, LDLR, LDLRP, and LRP1 proteins.
Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12M 1/00 - Apparatus for enzymology or microbiology
C12M 1/24 - Apparatus for enzymology or microbiology tube or bottle type
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
83.
TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY
The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells.
C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
84.
Mixing and microfluidic apparatuses related thereto
The application relates to microfluidic apparatus and methods of use thereof. Provided in one example is a microfluidic device comprising: a first fluidic input and a second fluidic input; and a fluidic intersection channel to receive fluid from the first fluidic input and the second fluidic input, wherein the fluidic intersection channel opens into a first mixing chamber on an upper region of a first side of the first mixing chamber, wherein the first mixing chamber has a length, a width, and a depth, wherein the depth is greater than about 1.5 times a depth of the fluidic intersection channel; an outlet channel on an upper region of a second side of the first mixing chamber, wherein the outlet channel has a depth that is less than the depth of the first mixing chamber, and wherein an opening of the outlet channel is offset along a width of the second side of the first mixing chamber relative to the fluidic intersection.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
B01F 23/40 - Mixing liquids with liquidsEmulsifying
B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
The present disclosure relates to lipid mixtures comprising lipidated cationic peptide compounds, such as tertiary amino lipidated and/or PEGylated cationic peptide compounds or lipitoids, for nucleic acid delivery. More specifically, the present disclosure relates to lipid nanoparticle formulations comprising lipidated cationic peptide compounds and other lipid components including structural lipid, phospholipid and shielding lipids. The present disclosure also relates to methods of preparing and using the lipid mixtures.
The application relates to microfluidic apparatus and methods of use thereof. Provided in one example is a microfluidic device comprising: a first fluidic input and a second fluidic input; and a fluidic intersection channel to receive fluid from the first fluidic input and the second fluidic input, wherein the fluidic intersection channel opens into a first mixing chamber on an upper region of a first side of the first mixing chamber, wherein the first mixing chamber has a length, a width, and a depth, wherein the depth is greater than about 1.5 times a depth of the fluidic intersection channel; an outlet channel on an upper region of a second side of the first mixing chamber, wherein the outlet channel has a depth that is less than the depth of the first mixing chamber, and wherein an opening of the outlet channel is offset along a width of the second side of the first mixing chamber relative to the fluidic intersection.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
F04B 19/00 - Machines or pumps having pertinent characteristics not provided for in, or of interest apart from, groups
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
B01F 23/40 - Mixing liquids with liquidsEmulsifying
B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Active chemical ingredients, including m-RNA, for use in the
manufacture of anti-cancer drugs; chemical solutions and
preparations consisting of pre-mixed reactants and reagents
for scientific and research use in connection with
transcription and translation of nucleic acid; chemical
solutions and preparations consisting of pre-mixed reactants
and reagents used to transfect nucleic acid into cells in
the field of scientific research; active chemical
ingredients for use in manufacture of anti-cancer drugs;
protein arrays and nucleotide arrays for scientific use;
nucleic acids, proteins and peptides for laboratory use;
diagnostic preparations for scientific or research use other
than for medical purposes; macromolecules, namely, nucleic
acid sequences and proteins, used for pharmaceutical
manufacturing and scientific purposes. Macromolecules, namely, nucleic acid sequences and proteins,
used for medical purposes; nucleic acid sequences and
chemical reagents for medical purposes; protein arrays and
nucleotide arrays for medical laboratory use; diagnostic
preparations for clinical or medical laboratory use. Cartridges and DNA chips to receive and preserve biological
samples for use in RNA transcription; scientific apparatus
and instruments for manufacturing m-RNA and parts and
fittings therefore; laboratory apparatus and instruments for
transcription of RNA from DNA and translation to m-RNA;
scientific apparatus for receiving DNA samples, transcribing
RNA, and producing m-RNA molecules for use in identifying
and/or manufacturing therapeutic drugs to treat human
diseases. Business consulting and management in the field of clinical
trials, namely, clinical data and regulatory submission
management on behalf of medical, biopharmaceutical and
biotechnology companies to assist them with clinical
research, clinical trials and applications for drug
approval; compiling data for research purposes in the field
of medical science and medical consultancy. Consulting services in the fields of biotechnology,
pharmaceutical research and development and genetic
sciences; DNA analysis services for scientific research
purposes; medical and scientific research, in particular in
the fields of prevention and treatment cancer; providing
scientific research information, consultancy, and advisory
services, in particular in the fields of prevention and
treatment of cancer treatment; conducting early evaluations
in the field of new pharmaceuticals; consulting services in
the fields of biotechnology and pharmaceutical research;
pharmaceutical product development services; pharmaceutical
product evaluation services; pharmaceutical research and
development; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; research and development of pharmaceuticals for the
treatment of cancer; technical research in the field of
pharmaceutical studies; development of platform technology,
namely, cancer immunotherapy platforms for manufacturing
therapeutics; and consulting services for others in the
field of design, planning, and implementation of clinical
trials; design, engineering, research, development and
testing services in the field of nucleic acid sciences for
medical, scientific and technological applications;
scientific research; scientific research in the fields of
pharmaceuticals, medicine, biologics, biotherapeutics,
biosimilars and therapeutics. Medical services, in particular providing therapy and
vaccination approaches for treating and preventing cancer,
infectious diseases and immunological diseases; veterinary
services, in particular providing therapy and vaccination
approaches for treating and preventing cancer, infectious
diseases, and immunological diseases; medical, veterinary
and pharmaceutical consultation; medical and veterinary
diagnostic testing, monitoring and reporting services;
providing medical information, consultancy, and advisory
services, in particular in the fields of treatment and
prevention of immunological diseases, cancer treatment,
prevention of cancer, treatment of infectious diseases, and
prevention of infectious diseases; medical services, namely,
providing therapies for treating cancer, medical and
pharmaceutical consultation; medical diagnostic testing,
monitoring and reporting services; genetic testing for
medical purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Active chemical ingredients, including m-RNA, for use in the
manufacture of anti-cancer drugs; chemical solutions and
preparations consisting of pre-mixed reactants and reagents
for scientific and research use in connection with
transcription and translation of nucleic acid; chemical
solutions and preparations consisting of pre-mixed reactants
and reagents used to transfect nucleic acid into cells in
the field of scientific research; active chemical
ingredients for use in manufacture of anti-cancer drugs;
protein arrays and nucleotide arrays for scientific use;
nucleic acids, proteins and peptides for laboratory use;
diagnostic preparations for scientific or research use other
than for medical purposes; macromolecules, namely, nucleic
acid sequences and proteins, used for pharmaceutical
manufacturing and scientific purposes. Macromolecules, namely, nucleic acid sequences and proteins,
used for medical purposes; nucleic acid sequences and
chemical reagents for medical purposes; protein arrays and
nucleotide arrays for medical laboratory use; diagnostic
preparations for clinical or medical laboratory use. Cartridges and DNA chips to receive and preserve biological
samples for use in RNA transcription; scientific apparatus
and instruments for manufacturing m-RNA and parts and
fittings therefore; laboratory apparatus and instruments for
transcription of RNA from DNA and translation to m-RNA;
scientific apparatus for receiving DNA samples, transcribing
RNA, and producing m-RNA molecules for use in identifying
and/or manufacturing therapeutic drugs to treat human
diseases. Business consulting and management in the field of clinical
trials, namely, clinical data and regulatory submission
management on behalf of medical, biopharmaceutical and
biotechnology companies to assist them with clinical
research, clinical trials and applications for drug
approval; compiling data for research purposes in the field
of medical science and medical consultancy. Consulting services in the fields of biotechnology,
pharmaceutical research and development and genetic
sciences; DNA analysis services for scientific research
purposes; medical and scientific research, in particular in
the fields of prevention and treatment cancer; providing
scientific research information, consultancy, and advisory
services, in particular in the fields of prevention and
treatment of cancer treatment; conducting early evaluations
in the field of new pharmaceuticals; consulting services in
the fields of biotechnology and pharmaceutical research;
pharmaceutical product development services; pharmaceutical
product evaluation services; pharmaceutical research and
development; providing medical and scientific research
information in the field of pharmaceuticals and clinical
trials; research and development of pharmaceuticals for the
treatment of cancer; technical research in the field of
pharmaceutical studies; development of platform technology,
namely, cancer immunotherapy platforms for manufacturing
therapeutics; and consulting services for others in the
field of design, planning, and implementation of clinical
trials; design, engineering, research, development and
testing services in the field of nucleic acid sciences for
medical, scientific and technological applications;
scientific research; scientific research in the fields of
pharmaceuticals, medicine, biologics, biotherapeutics,
biosimilars and therapeutics. Medical services, in particular providing therapy and
vaccination approaches for treating and preventing cancer,
infectious diseases and immunological diseases; veterinary
services, in particular providing therapy and vaccination
approaches for treating and preventing cancer, infectious
diseases, and immunological diseases; medical, veterinary
and pharmaceutical consultation; medical and veterinary
diagnostic testing, monitoring and reporting services;
providing medical information, consultancy, and advisory
services, in particular in the fields of treatment and
prevention of immunological diseases, cancer treatment,
prevention of cancer, treatment of infectious diseases, and
prevention of infectious diseases; medical services, namely,
providing therapies for treating cancer, medical and
pharmaceutical consultation; medical diagnostic testing,
monitoring and reporting services; genetic testing for
medical purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical solutions and preparations consisting of pre-mixed
reactants and reagents for scientific and research use in
connection with amplification, analysis, transport or
delivery of nucleic acids.
The application relates to microfluidic apparatus and methods of use thereof. Provided in one example is a microfluidic device comprising: a first fluidic input and a second fluidic input; and a fluidic intersection channel to receive fluid from the first fluidic input and the second fluidic input, wherein the fluidic intersection channel opens into a first mixing chamber on an upper region of a first side of the first mixing chamber, wherein the first mixing chamber has a length, a width, and a depth, wherein the depth is greater than about 1.5 times a depth of the fluidic intersection channel; an outlet channel on an upper region of a second side of the first mixing chamber, wherein the outlet channel has a depth that is less than the depth of the first mixing chamber, and wherein an opening of the outlet channel is offset along a width of the second side of the first mixing chamber relative to the fluidic intersection.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
(1) Chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with amplification, analysis, transport or delivery of nucleic acids.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer services, namely, providing temporary use of non-downloadable cloud-based computer software to analyze and/or design macromolecule synthesis in the field of pharmaceutical and/or science research accessed using a portal interface; Consulting services in the field of cloud computing pertaining to the synthesis of macromolecules; Providing an online network environment featuring technology that enables users to analyze and/or design macromolecule synthesis
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer services, namely, providing temporary use of non-downloadable cloud-based computer software to analyze and/or design macromolecule synthesis in the field of pharmaceutical and/or science research accessed using a portal interface; Consulting services in the field of cloud computing pertaining to the synthesis of macromolecules; Providing an online network environment featuring technology that enables users to analyze and/or design macromolecule synthesis
42 - Scientific, technological and industrial services, research and design
Goods & Services
Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic sciences; Compiling data for research purposes in the field of medical science and medical consultancy; DNA analysis services for scientific research purposes; Medical and scientific research, in particular in the fields of prevention and treatment cancer; providing scientific research information, consultancy, and advisory services, in particular in the fields of prevention and treatment of cancer treatment; Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; and consulting services for others in the field of design, planning, and implementation of clinical trials; Design, engineering, research, development and testing services in the field of nucleic acid sciences for medical, scientific and technological applications; Scientific research; scientific research in the fields of pharmaceuticals, medicine, biologics, biotherapeutics, biosimilars and therapeutics
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Active chemical ingredients, including m-RNA, for use in the manufacture of anti-cancer drugs; Chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with transcription and translation of nucleic acid; Chemical solutions and preparations consisting of pre-mixed reactants and reagents used to transfect nucleic acid into cells in the field of scientific research; Active chemical ingredients for use in manufacture of anti-cancer drugs; Protein arrays and nucleotide arrays for scientific and medical laboratory use; Nucleic acids, proteins and peptides for laboratory use; Diagnostic preparations for scientific or research use other than for medical purposes; Diagnostic preparations for clinical or medical laboratory use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Macromolecules, namely, nucleic acid sequences and proteins used for medical and/or pharmaceutical purposes; Nucleic acid sequences and chemical reagents for medical and/or pharmaceutical purposes
09 - Scientific and electric apparatus and instruments
Goods & Services
Cartridges and DNA chips to receive and preserve biological samples for use in RNA transcription; Scientific apparatus and instruments for manufacturing m-RNA and replacement parts and fittings therefor; Laboratory apparatus and instruments for transcription of RNA from DNA and translation to m-RNA; Scientific apparatus for receiving DNA samples, transcribing RNA, and producing m-RNA molecules for use in identifying and/or manufacturing therapeutic drugs to treat human diseases
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Active chemical ingredients, including m-RNA, for use in the manufacture of anti-cancer drugs; chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with transcription and translation of nucleic acid; chemical solutions and preparations consisting of pre-mixed reactants and reagents used to transfect nucleic acid into cells in the field of scientific research; active chemical ingredients for use in manufacture of anti-cancer drugs; protein arrays and nucleotide arrays for scientific use; nucleic acids, proteins and peptides for laboratory use; macromolecules, namely, nucleic acid sequences and proteins, used for pharmaceutical manufacturing and scientific purposes.
(2) Macromolecules, namely, nucleic acid sequences and proteins, used for medical purposes; nucleic acid sequences and diagnostic chemical reagents for medical purposes; protein arrays and nucleotide arrays for medical laboratory use; diagnostic preparations for clinical or medical laboratory use.
(3) Cartridges and DNA chips to receive and preserve biological samples for use in RNA transcription; scientific apparatus and instruments for manufacturing m-RNA, namely, a system consisting of microfluidic chips and flow cells, and parts and fittings therefore; laboratory apparatus and instruments for transcription of RNA from DNA and translation to m-RNA, namely, a system consisting of microfluidic chips and flow cells; scientific apparatus for receiving DNA samples, transcribing RNA, and producing m-RNA molecules, namely, a system consisting of microfluidic chips and flow cells, for use in identifying and manufacturing therapeutic drugs to treat human diseases. (1) Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Compiling of statistical data for research purposes in the field of medical science and medical consultancy; Compiling of data from clinical trials for research purposes in the field of medical science and medical consultancy.
(2) Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic sciences; DNA analysis services for scientific research purposes; medical and scientific research, in particular in the fields of prevention and treatment cancer; providing scientific research information, consultancy, and advisory services, in particular in the fields of prevention and treatment of cancer treatment; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; and consulting services for others in the field of design, planning, and implementation of clinical trials; design, engineering, research, development and testing services in the field of nucleic acid sciences for medical, scientific and technological applications; scientific research in the field of anti-cancer drugs; scientific research in the fields of pharmaceuticals, medicine, biologics, biotherapeutics, biosimilars and therapeutics.
(3) Medical services, in particular providing therapy and vaccination approaches for treating and preventing cancer, infectious diseases and immunological diseases; veterinary services, in particular providing therapy and vaccination approaches for treating and preventing cancer, infectious diseases, and immunological diseases; medical and veterinary diagnostic testing, monitoring and reporting services; providing medical information, consultancy, and advisory services, in particular in the fields of treatment and prevention of immunological diseases, cancer treatment, prevention of cancer, treatment of infectious diseases, and prevention of infectious diseases; medical consultation services, namely, providing therapies for treating cancer, and pharmaceutical consultation; medical diagnostic testing, monitoring and reporting services; genetic testing for medical purposes.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Active chemical ingredients, including m-RNA, for use in the manufacture of anti-cancer drugs; chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with transcription and translation of nucleic acid; chemical solutions and preparations consisting of pre-mixed reactants and reagents used to transfect nucleic acid into cells in the field of scientific research; active chemical ingredients for use in manufacture of anti-cancer drugs; protein arrays and nucleotide arrays for scientific use; nucleic acids, proteins and peptides for laboratory use; diagnostic preparations for scientific or research use other than for medical purposes; macromolecules, namely, nucleic acid sequences and proteins, used for pharmaceutical manufacturing and scientific purposes.
(2) Macromolecules, namely, nucleic acid sequences and proteins, used for medical purposes; nucleic acid sequences and chemical reagents for medical purposes; protein arrays and nucleotide arrays for medical laboratory use; diagnostic preparations for clinical or medical laboratory use.
(3) Cartridges and DNA chips to receive and preserve biological samples for use in RNA transcription; scientific apparatus and instruments for manufacturing m-RNA and parts and fittings therefore; laboratory apparatus and instruments for transcription of RNA from DNA and translation to m-RNA; scientific apparatus for receiving DNA samples, transcribing RNA, and producing m-RNA molecules for use in identifying and/or manufacturing therapeutic drugs to treat human diseases. (1) Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Compiling of statistical data for research purposes in the field of medical science and medical consultancy; Compiling of data from clinical trials for research purposes in the field of medical science and medical consultancy.
(2) Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic sciences; DNA analysis services for scientific research purposes; medical and scientific research, in particular in the fields of prevention and treatment cancer; providing scientific research information, consultancy, and advisory services, in particular in the fields of prevention and treatment of cancer treatment; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; and consulting services for others in the field of design, planning, and implementation of clinical trials; design, engineering, research, development and testing services in the field of nucleic acid sciences for medical, scientific and technological applications; scientific research; scientific research in the fields of pharmaceuticals, medicine, biologics, biotherapeutics, biosimilars and therapeutics.
(3) Medical services, in particular providing therapy and vaccination approaches for treating and preventing cancer, infectious diseases and immunological diseases; veterinary services, in particular providing therapy and vaccination approaches for treating and preventing cancer, infectious diseases, and immunological diseases; medical, veterinary and pharmaceutical consultation; medical and veterinary diagnostic testing, monitoring and reporting services; providing medical information, consultancy, and advisory services, in particular in the fields of treatment and prevention of immunological diseases, cancer treatment, prevention of cancer, treatment of infectious diseases, and prevention of infectious diseases; medical services, namely, providing therapies for treating cancer, medical and pharmaceutical consultation; medical diagnostic testing, monitoring and reporting services; genetic testing for medical purposes.
100.
METHODS AND APPARATUSES FOR MANUFACTURING FOR REMOVING MATERIAL FROM A THERAPEUTIC COMPOSITION
Methods and apparatuses for making and using therapeutics, including in particular mRNA therapeutics, that separate double- stranded RNA from single- stranded RNA as part of a continuous flow. These methods and apparatuses may include formulation of an RNA therapeutic using a permeable insert integrated into a microfluidic path device. In particular, these methods and apparatuses may include formulation of an RNA therapeutic by removing dsRNA from a solution of RNA by within a microfluidic path device including a cellulose material.
